Overview
The cannabis maker's Q2 revenue rose 3% to $217.5 mln
Adjusted net loss for Q2 improved slightly compared to last year
Company holds $292 mln in cash and marketable securities
Outlook
Tilray expects U.S. federal cannabis rescheduling to unlock new market opportunities
Company plans to leverage existing infrastructure for U.S. medical cannabis expansion
Tilray reaffirms fiscal 2026 Adjusted EBITDA guidance at $62 mln – $72 mln
Result Drivers
INTERNATIONAL CANNABIS GROWTH - International medical cannabis revenue increased by 36%, contributing to overall cannabis revenue growth
DISTRIBUTION SEGMENT - Distribution net revenue reached a record high of $85.3 million, up from $67.6 million
BEVERAGE REVENUE DECLINE - Beverage net revenue decreased to $50.1 million from $63.1 million, impacting overall revenue growth
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$217.51 mln
Q2 Adjusted EPS
-$0.02
Q2 EPS
-$0.41
Q2 Net Income
-$43.51 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Tilray Brands Inc is C$13.60, about 9.2% above its January 7 closing price of C$12.45
Press Release: ID:nGNXCLswC
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)